Form 4: Crinetics Pharmaceuticals Director Matthew Fust Acquires Significant Equity Holdings

Matthew K. Fust, a Director at Crinetics Pharmaceuticals, Inc. (CRNX), reported the acquisition of 6,900 restricted stock units and 10,350 stock options as part of his compensation.

Summary

• Matthew K. Fust, a Director of Crinetics Pharmaceuticals, Inc. (CRNX), reported changes in his beneficial ownership of the company's securities.
• On June 11, 2025, Mr. Fust acquired 6,900 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs are set to vest 100% on the earlier of the first anniversary of the grant date or the next occurring annual meeting of the Issuer's stockholders, contingent on Mr. Fust's continued service on the board.
• Additionally, on June 11, 2025, Mr. Fust acquired 10,350 stock options with an exercise price of $32.33 per share.
• These stock options will vest and become exercisable on the earlier of the first anniversary of the grant date or the next occurring annual meeting of the Issuer's stockholders, also subject to his continued board service.
• The stock options have an expiration date of June 11, 2035.
• Following these transactions, Mr. Fust beneficially owns 28,836 shares of Common Stock directly and 10,350 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director's acquisition of equity, which often signals confidence in the company's future. However, it is a routine compensation event rather than a discretionary open-market purchase.

Positives

• The acquisition of additional equity (RSUs and stock options) by a director can signal confidence in the company's future prospects and align the director's interests with those of shareholders.
• The grant of equity compensation is a standard practice for retaining and incentivizing experienced board members.

Risks

• The value of the acquired restricted stock units and stock options is subject to the future performance of Crinetics Pharmaceuticals' stock price.
• Vesting of both the RSUs and stock options is contingent upon the director's continued service on the board, meaning forfeiture could occur if service ceases before vesting.

Future Outlook

The acquired restricted stock units and stock options are subject to future vesting conditions, which will occur on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, provided the director continues his service.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to align management and board interests with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units and stock options as part of director compensation is a standard industry practice across various sectors, including biotechnology and pharmaceuticals.
• The vesting schedule, tied to continued service and annual meetings, is typical for such equity awards, aiming to incentivize long-term commitment and performance.

Related Party Transactions

• The acquisition of restricted stock units and stock options by a director from the company constitutes a related party transaction, which is a standard form of compensation for board service.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.
• Employees: This specific filing does not directly impact the broader employee base, as it pertains to director compensation.

Next Steps

• The restricted stock units and stock options will vest according to their specified schedules, either on the first anniversary of the grant date or the next annual meeting of stockholders, subject to continued board service.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership, Equity Compensation